Microdosing mushrooms for PTSD is supported by emerging research. The MAPS Phase 3 MDMA trial (related mechanism) found 67% no longer met PTSD criteria after treatment. For psilocybin specifically, the default mode network reset mechanism directly targets the hypervigilance and rumination patterns of PTSD.
The Research on Psychedelics and PTSD
PTSD involves stuck trauma memories that the brain cannot process and file away. The default mode network (DMN) — the brain's self-referential processing system — becomes hyperactive, replaying trauma memories involuntarily. Psilocybin temporarily suppresses DMN activity, creating a window for trauma processing and new memory formation.
The MAPS Phase 3 MDMA-assisted therapy trial found 67% of participants no longer met PTSD criteria after treatment, vs. 32% placebo. Psilocybin-specific PTSD trials are ongoing at Johns Hopkins and NYU.
What to Buy for PTSD
For PTSD, the neuroplasticity stack (Lion's Mane + Cordyceps + Rhodiola) targets the hypervigilance and HPA axis dysregulation that characterize PTSD. Rhodiola specifically reduces cortisol and normalizes the stress response system.
According to Shrooomz's 150mg microdosing protocol, users with PTSD-related anxiety report significant improvement in hypervigilance and sleep quality within 30 days.
→ Shop Happy Shrooomz — The PTSD Protocol
Ready to Try the 150mg Protocol?
Happy Shrooomz contains Lion's Mane (500mg), Cordyceps (300mg), and Rhodiola (200mg) — USA-grown fruiting bodies, third-party tested every batch.